Fri, Aug 29, 2014, 11:17 AM EDT - U.S. Markets close in 4 hrs 43 mins

Recent

% | $
Quotes you view appear here for quick access.

ALLIQUA, INC. Message Board

  • amadeus942000 amadeus942000 Jul 23, 2013 9:13 AM Flag

    Hydrogel pain patch, big news

    Alliqua Initiates Proof-of-Principle Study of Transdermal Lidocaine Hydrogel Patch for Pain Relief
    Press Release: Alliqua, Inc. – 1 hour 40 minutes ago
    Email
    RecommendTweet
    Print
    RELATED QUOTES
    Symbol Price Change
    ALQA 0.08

    LANGHORNE, Pennsylvania, July 23, 2013 /PRNewswire/ --
    Alliqua, Inc. (ALQA) ("Alliqua" or the "Company") today announced the initiation of a preclinical proof-of-principle study of an experimental hydrogel patch containing lidocaine. Safety and tolerability of Alliqua's lidocaine hydrogel patches will be explored in an animal model. Further, the pharmacokinetic profile will be analyzed to determine the amount of systemic absorption and local lidocaine concentration in the skin immediately beneath the patch.
    "The ease of use, stability and compatibility with active ingredients make our hydrogels well suited for the transdermal delivery of a variety of compounds, including pain medications like lidocaine," commented James Sapirstein, chief executive officer of Alliqua Biomedical. "Our lidocaine patch development program is just the first in our effort to build a portfolio of products that leverage our hydrogel platform. We believe success in this proof-of-principle study for our lidocaine patch would increase the likelihood of success with other compounds and greatly enhances our efforts in this area. Beyond lidocaine, the Alliqua Biomedical division plans to explore transdermal delivery of dermatological, oncology, antibiotic and neurology products."
    The Company plans to develop lidocaine hydrogel patches for the treatment of localized acute pain, including post-operative pain, back pain, as well as pain associated with sports injuries and arthritis. Alliqua expects results from this preclinical proof-of-principle study later in the third quarter.
    "Lidocaine is an important therapeutic agent with a strong potential market opportunity," Mr. Sapirstein added. "Following successful completion of this proof-of-principle study, Alliqua intends to develop a clinical and development path forward based on discussions with the U.S. Food and Drug Administration as well as scientific advisers and potential partners."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ALQA really takes the cake! They put out absolutely irrelevant pieces of information to try and pump and dump. Today they speak of a topical lidocaine patch that they are commencing animal studies in. Someone should tell them that there HAS ALWAYS BEEN A TOPICAL LIDOCAINE AVAILABLE for YEARS!! It has been used in multiple disciplines in the practice of medicine. Well I guess you just can't keep a good huckster down!!! The players may have changed in management slightly but the playbook is as always!

      • 1 Reply to charleslusten
      • I don't think you really understood the message behind this study, but if you want me to decode it for you just let me know. This is the key part of this MSG :
        "The ease of use, stability and compatibility with active ingredients make our hydrogels well suited for the transdermal delivery of a variety of compounds, including pain medications like lidocaine," commented James Sapirstein, chief executive officer of Alliqua Biomedical. "Our lidocaine patch development program is just the first in our effort to build a portfolio of products that leverage our hydrogel platform. We believe success in this proof-of-principle study for our lidocaine patch would increase the likelihood of success with other compounds and greatly enhances our efforts in this area. Beyond lidocaine, the Alliqua Biomedical division plans to explore transdermal delivery of dermatological, oncology, antibiotic and neurology products."

 
ALQA
5.154+0.004(+0.08%)Aug 29 9:42 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.